Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer

Dean, Sarah J.; Perks, Claire M; Holly, Jeff M.P.; Bhoo-Pathy, Nirmala; Looi, Lai‐Meng; Mohammed, Nur Aishah Taib; Mun, Kein Seong; Teo, Soo‐Hwang; Koobotse, Moses O.; Yip, Cheng‐Har; Rhodes, Anthony

doi:10.1309/ajcpr11deayptusl

Cited by 47 publications

(42 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent immunohistological study by Dean et al [86], it was reported that loss of PTEN frequently takes place in TBNC and is associated with increased IGFBP-2 expression. In agreement with this finding is that activation of the PI3K/Akt pathway, presumably because of the loss of PTEN, is predictive of relapse-free survival (RFS) risk in patients with TNBC disease [82], suggesting that this pathway and its downstream effector IGFBP-2 might be deployed as potential novel therapeutic targets for patients with residual TNBCs.…”

Section: Igfbp-2 and Breast Cancermentioning

confidence: 99%

Physiology and pathophysiology of IGFBP-1 and IGFBP-2 – Consensus and dissent on metabolic control and malignant potential

Hoeflich

Russo

2015

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

Section: Igfbp-2 and Breast Cancermentioning

confidence: 99%

Physiology and pathophysiology of IGFBP-1 and IGFBP-2 – Consensus and dissent on metabolic control and malignant potential

Hoeflich

Russo

2015

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

“…This was consistent with all of the subsequent studies indicating that the expression of IGFBP-2 was regulated by the PI3K/AKT/mTOR pathway. An increase in tumour IGFBP-2 has also been associated with loss of PTEN in human breast cancer samples [55].…”

Section: Pten/igfbp-2 Interactionsmentioning

confidence: 99%

IGFBP-2/PTEN: A critical interaction for tumours and for general physiology?

Zeng

Perks

Holly

2015

Growth Hormone & IGF Research

Self Cite

View full text Add to dashboard Cite

“…PTEN inhibits AKT phosphorylation thereby regulating the PI3 K/Akt pathway [9]. PTEN loss is a frequent event in breast cancer with TNBC showing the highest loss than other breast cancer subgroups, and is significantly associated with younger age at onset of breast cancer and late stage [10,11]. Loss of PTEN in breast cancers has been associated with poor response to treatment and worse disease outcome through substantial increase in Akt signaling [12].…”

Section: Introductionmentioning

confidence: 99%

Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer

Beg

Siraj

Prabhakaran

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

PTEN is a tumor suppressor that negatively regulates the PI3 K-AKT signaling pathway which is involved in the pathogenesis of many different tumor types and serves as a prognostic marker in breast cancer. However, the significance of the role of PTEN in Middle Eastern ethnic breast cancer has not been explored especially with the fact that breast cancer originating from this ethnic population tend to behave more aggressively than breast cancer in the west. In this study, we analyzed PTEN alteration in a tissue microarray format containing more than 1000 primary breast cancers with clinical follow-up data. Tissue Microarray sections were analyzed for protein expression and copy number change using immunohistochemistry and fluorescence in situ hybridization. Loss of PTEN immunostaining was observed in 77 % of the cases. PTEN loss was significantly associated with large tumor size (p = 0.0030), high grade (p = 0.0281), tumor recurrence (p = 0.0333), and triple-negative breast cancers (p = 0.0086). PTEN loss in triple-negative breast cancers was significantly associated with rapid tumor cell proliferation (p = 0.0396) and poor prognosis (p = 0.0408). PTEN deletion was found only in 60 cases (6.4 %). Loss of PTEN protein expression occurs at high frequency in Middle Eastern breast cancer. PTEN inactivation may potentially lead to an aggressive behavior of tumor cells through stimulation of tumor cell proliferation. Furthermore, PTEN signaling pathway might be used as potential therapeutic target in triple-negative breast cancers since loss of its expression is shown to be significantly associated with this aggressive subtype of breast cancer.

show abstract

Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer

Abstract: PTEN loss is a frequent event in triple-negative breast cancers and is significantly associated with younger age at onset of breast cancer, late stage, and IGFBP2 expression.

Cited by 47 publications

References 43 publications

Physiology and pathophysiology of IGFBP-1 and IGFBP-2 – Consensus and dissent on metabolic control and malignant potential

Physiology and pathophysiology of IGFBP-1 and IGFBP-2 – Consensus and dissent on metabolic control and malignant potential

IGFBP-2/PTEN: A critical interaction for tumours and for general physiology?

Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer

Contact Info

Product

Resources

About